|
|
Post by longliner on Mar 9, 2024 13:13:49 GMT -5
Fortunately for MNKD and Afrezza, your experience is anecdotal. The studies are adding up. Millions of very lucky children are on the horizon for Afrezza. Indeed. My experience, Ginger's experience, and the experiences of the other diabetics I know are all anecdotal and why we have trials. Studies are interesting in so far as they suggest ideas for proper trials such as INHALE-1 and INHALE-3. From ATTD it sounds like the proper trial data is adding up as well for Afrezza! Millions of lucky kids will (hopefully) soon have access to Afrezza, the best in class (only) Ultra rapid acting insulin! I realize children love needle's, I guess they'll have to adapt to a quick inhale.  |
|
|
|
Post by lennymnkd on Mar 9, 2024 15:25:41 GMT -5
|
|
|
|
Post by lennymnkd on Mar 9, 2024 15:27:25 GMT -5
Good company ! Not so sure about sanofi 🤔…but you never know.
|
|
|
|
Post by sayhey24 on Mar 9, 2024 15:45:49 GMT -5
Good company ! Not so sure about sanofi 🤔…but you never know. When Chris Viehbacher was there doing the deal with them made a lot of sense. However, Chris found out real fast BP wanted no part of afrezza and were willing to do anything to stop it and Chris lost his job. |
|
|
|
Post by cppoly on Mar 11, 2024 7:19:28 GMT -5
|
|
|
|
Post by akemp3000 on Mar 11, 2024 14:49:13 GMT -5
Chris Viehbacher, Sanofi's first non-French leader, lost his job because he wasn't French and wanted to move his Sanofi office to Boston. This was insulting to the French company. The company line however was the board didn't like his management style. At the time, Afrezza wasn't even on the radar of importance. It only became a headline when Viehbacher's French replacement, Brandicort, immediately tanked the Mannkind partnership. This was because Brandicort had a personal history of losing millions with Pfizer's failed inhaled insulin Exubera. He wanted no part of a new attempt at inhaled insulin.
|
|
|
|
Post by Chris-C on Mar 12, 2024 11:34:26 GMT -5
Chris Viehbacher, Sanofi's first non-French leader, lost his job because he wasn't French and wanted to move his Sanofi office to Boston. This was insulting to the French company. The company line however was the board didn't like his management style. At the time, Afrezza wasn't even on the radar of importance. It only became a headline when Viehbacher's French replacement, Brandicort, immediately tanked the Mannkind partnership. This was because Brandicort had a personal history of losing millions with Pfizer's failed inhaled insulin Exubera. He wanted no part of a new attempt at inhaled insulin. Spot on. This is a succinct and accurate summary of the fiasco with Sanofi. It was a case of MNKD being with the wrong company at the wrong time. FWIW, I'm not interested in a buyout unless it is at least 3x current share price or higher. i doubt that will happen.. I'd rather stick with a management team that seems to be doing very well. There is more to come with MNKDs fortunes, IMO. Chris C |
|
|
|
Post by sayhey24 on Mar 12, 2024 19:41:43 GMT -5
Chris Viehbacher, Sanofi's first non-French leader, lost his job because he wasn't French and wanted to move his Sanofi office to Boston. This was insulting to the French company. The company line however was the board didn't like his management style. At the time, Afrezza wasn't even on the radar of importance. It only became a headline when Viehbacher's French replacement, Brandicort, immediately tanked the Mannkind partnership. This was because Brandicort had a personal history of losing millions with Pfizer's failed inhaled insulin Exubera. He wanted no part of a new attempt at inhaled insulin. Why would Sanofi hire a guy who they knew was a loser? He bought Exubera from Sanofi. Sanofi made a $B from the sale and laughed all the way to the bank. Of course the board knew of Exubera and afrezza and what Al Mann was doing. Then Brandicourt at Pfizer gets upstaged by Al Mann and Chris Viehbacher. Yep, that sounds like the perfect hire? Then the guy goes on to lose $Bs at Sanofi. This was all because Sanofi didn't want Chris to have an office in Boston? They just built "Sanofi at Cambridge Crossing", their new state-of-the-art facility or so they say. I would say they like Boston. I think its a little chilly but they do have that nice Freedom Trail. The whole French thing was in the news reports. What was not was that Viehbacher was about to disrupt the entire diabetes market, especially the emerging GLP1 market. Maybe the news reports were right. He was not French. Then again our news agencies often have a bad track record. Things like telling us Saddam Hussein had WMD's comes to mind when what Saddam had was selling oil for Euro's and not $$$. Destabilizing the $$$ was a big deal. Disrupting a $100B diabetes market was a big deal. What was Chris thinking? Then again, what was Saddam thinking? |
|
